An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

NCT05522387 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor resource allocation

Conditions

Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders

Interventions

DRUG: XPro1595

Sponsor

Inmune Bio, Inc.